Osteopontin expression in gestational trophoblastic diseases: correlation with expression of the adhesion molecule, CEACAM1.
The human placenta is a complex tissue with multiple endocrine and nutritional functions and a unique capacity for rapid proliferation but tightly controlled invasion, differentiating it from malignant tumors. Osteopontin (OPN) is a glycoprotein of the extracellular matrix, which has been shown to mediate cellular migration and invasion and to contribute to tumorigenesis in several types of cancers. OPN also could be implicated in regulating implantation and placentation by promoting cellular migration and invasion in a placenta-specific fashion. We could demonstrate the expression pattern of OPN in the normal human placenta in which it is localized in the extravillous (intermediate) trophoblast and the villous cytotrophoblast. CEACAM1 is an adhesion molecule, which we have recently found to be expressed at the maternal-fetal interface of the normal placenta with a localization to the extravillous (invasive) trophoblast and in gestational trophoblastic disease (GTD) and also to be potentially implicated in trophoblast invasion and tumorigenesis. Both OPN and CEACAM1 have been shown to interact with integrin beta3. The purpose of this study was to investigate the expression pattern of OPN in GTD and to correlate it with the expression of CEACAM1. To analyze the expression of OPN, we performed immunohistochemistry on a total of 27 cases of GTD, including 21 hydatidiform moles and 6 choriocarcinomas, which had previously been characterized with respect to their CEACAM1 expression. Hydatidiform moles showed a positivity for OPN in villous cytotrophoblast and in the trophoblast proliferations on the villous surface. The strongest OPN expression could be observed in the choriocarcinomas with a heterogenous OPN expression pattern. CEACAM1 had shown similar results and was found to be expressed in choriocarcinoma. The expression pattern of osteopontin in gestational trophoblastic diseases indicates that it might play a role in the pathogenesis of GTD (possibly as a functional complex with CEACAM1 and integrin beta3) and might be useful as an additional diagnostic marker for such lesions.
Briese
Juliane
J
Institute of Pathology, Department of Gynecopathology, University Hospital Eppendorf, 20246 Hamburg, Germany. j.briese@uke.uni-hamburg.de
Oberndörfer
Marine
M
Schulte
Heinrich M
HM
Löning
Thomas
T
Bamberger
A M
AM
D015703:Antigens, CD / Q000096:biosynthesis* / Q000235:genetics; D015815:Cell Adhesion Molecules; D005260:Female; D015870:Gene Expression; D031901:Gestational Trophoblastic Disease / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D053495:Osteopontin; D010920:Placenta / Q000378:metabolism / Q000502:physiology; D011247:Pregnancy; D012189:Retrospective Studies; D012795:Sialoglycoproteins / Q000096:biosynthesis* / Q000235:genetics
D015703:Antigens, CD; C069847:CD66 antigens; D015815:Cell Adhesion Molecules; C506895:SPP1 protein, human; D012795:Sialoglycoproteins; D053495:Osteopontin